R
Ray McDermott
Researcher at Boston Children's Hospital
Publications - 89
Citations - 7119
Ray McDermott is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 18, co-authored 62 publications receiving 4052 citations. Previous affiliations of Ray McDermott include Trinity College, Dublin & University College Dublin.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman,Ray McDermott,Joseph Leach,Sara Lonardi,Heinz-Josef Lenz,Michael A. Morse,Jayesh Desai,Andrew G. Hill,Michael D. Axelson,Rebecca A. Moss,Monica V. Goldberg,Z. Alexander Cao,Jean Marie Ledeine,G. Maglinte,Scott Kopetz,Thierry André +15 more
TL;DR: Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.
Journal ArticleDOI
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman,Sara Lonardi,Ka Yeung Mark Wong,Heinz-Josef Lenz,Fabio Gelsomino,Massimo Aglietta,Michael A. Morse,Eric Van Cutsem,Ray McDermott,Andrew Hill,Michael B. Sawyer,Alain Hendlisz,Bart Neyns,Magali Svrcek,Rebecca A. Moss,Jean Marie Ledeine,Z. Alexander Cao,Shital Kamble,Scott Kopetz,Thierry André +19 more
TL;DR: Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.
Journal ArticleDOI
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis,Andrew J. Martin,Martin R. Stockler,Stephen Begbie,Kim N. Chi,Simon Chowdhury,Xanthi Coskinas,Mark Frydenberg,Wendy Hague,Lisa G. Horvath,Lisa G. Horvath,Anthony M. Joshua,Anthony M. Joshua,Nicola Jane Lawrence,Gavin Marx,Gavin Marx,John McCaffrey,Ray McDermott,Margaret McJannett,Scott North,Francis Parnis,Wendy R. Parulekar,David Pook,M. Neil Reaume,M. Neil Reaume,Shahneen Sandhu,Alvin Tan,T. Hsiang Tan,Alastair Thomson,Emily Tu,Francisco E. Vera-Badillo,Scott Williams,Sonia Yip,Alison Yan Zhang,Robert Zielinski,Christopher Sweeney +35 more
TL;DR: Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression.
Journal ArticleDOI
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong,Steven G. DuBois,Shivaani Kummar,Anna F. Farago,Catherine M. Albert,Kristoffer Staal Rohrberg,Cornelis M. van Tilburg,Cornelis M. van Tilburg,Ramamoorthy Nagasubramanian,Jordan Berlin,Noah Federman,Leo Mascarenhas,Birgit Geoerger,Afshin Dowlati,Alberto S. Pappo,Stefan S. Bielack,François Doz,Ray McDermott,Jyoti D. Patel,Russell J. Schilder,Makoto Tahara,Stefan M. Pfister,Stefan M. Pfister,Olaf Witt,Olaf Witt,Marc Ladanyi,Erin R. Rudzinski,Shivani Nanda,Barrett H. Childs,Theodore W. Laetsch,David M. Hyman,David M. Hyman,Alexander Drilon,Alexander Drilon +33 more
TL;DR: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active and indicate that long-term administration of larot rectinib are feasible.
Journal ArticleDOI
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Martin Bambury,Eric Voog,Jingsong Zhang,Josep M. Piulats,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Celestia S. Higano,Laurence Eliot Miles Krieger,Cora N. Sternberg,Simon Paul Watkins,Darrin Despain,Andrew Simmons,Andrea Loehr,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury,Simon Chowdhury +27 more
TL;DR: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.